US Stock MarketDetailed Quotes
PRQR ProQR Therapeutics
- 1.9850
- +0.0050+0.25%
Close May 14 16:00 ET
- 1.9700
- -0.0150-0.76%
Post 19:24 ET
162.10MMarket Cap-5560P/E (TTM)
2.0500High1.9300Low88.26KVolume2.0200Open1.9800Pre Close173.87KTurnover0.15%Turnover RatioLossP/E (Static)81.66MShares3.290052wk High4.31P/B114.73MFloat Cap1.110052wk Low--Dividend TTM57.80MShs Float27.6000Historical High--Div YieldTTM6.06%Amplitude0.5300Historical Low1.9690Avg Price1Lot Size
ProQR Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -133.83%-15.13M | 131.45%21.55M | 70.16%-5.32M | 51.13%-7.51M | 30.30%-10.35M | 318.52%44.73M | -163.37%-68.51M | -571.15%-17.83M | -90.69%-15.36M | -48.75%-14.84M |
| Net income from continuing operations | 13.52%-7.66M | 56.80%-27.74M | 58.77%-5.48M | 76.74%-5.42M | 40.84%-7.98M | 37.27%-8.86M | -5.60%-64.2M | 23.38%-13.3M | -54.65%-23.3M | 14.41%-13.48M |
| Operating gains losses | 110.15%68K | 59.93%-1.08M | 209.52%1.92M | -140.01%-1.61M | -256.45%-221K | 82.16%-670K | -270.88%-2.71M | -396.28%-1.75M | 439.84%4.01M | -287.88%-62K |
| Depreciation and amortization | 25.87%691K | -0.32%2.51M | -2.67%728K | 4.90%642K | 0.51%594K | -3.68%549K | 8.24%2.52M | 35.51%748K | 12.50%612K | -1.83%591K |
| Deferred tax | --3K | -181.25%-78K | --5K | -220.29%-83K | --0 | --0 | -17.95%96K | --0 | 97.14%69K | -62.26%20K |
| Other non cash items | -458.82%-488K | -463.48%-6.01M | -320.62%-5.72M | 39.40%-363K | 75.25%-571K | -83.45%136K | -12.44%1.65M | 530.90%2.59M | -125.19%-599K | -193.63%-2.31M |
| Change In working capital | -117.64%-9.22M | 1,080.89%48.96M | 141.27%2.3M | -155.67%-2.01M | -495.41%-3.62M | 1,423.80%52.29M | -119.95%-4.99M | -128.74%-5.56M | -25.41%3.61M | -48.37%916K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -133.83%-15.13M | 131.45%21.55M | 70.16%-5.32M | 51.13%-7.51M | 30.30%-10.35M | 318.52%44.73M | -163.37%-68.51M | -571.15%-17.83M | -90.69%-15.36M | -48.75%-14.84M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -19,823.60%-17.73M | 709.40%4.28M | 26,215.79%5M | -37.80%-339K | -27.27%-294K | 63.52%-89K | -65.18%-702K | 111.45%19K | -40.57%-246K | -344.23%-231K |
| Net PPE purchase and sale | -722.47%-732K | -86.75%-1.31M | -3,200.00%-589K | -37.80%-339K | -27.27%-294K | 63.52%-89K | -65.18%-702K | 111.45%19K | -40.57%-246K | -344.23%-231K |
| Net intangibles purchase and sale | ---- | --7.94M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | ---17M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net other investing changes | ---- | ---2.35M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -19,823.60%-17.73M | 709.40%4.28M | 26,215.79%5M | -37.80%-339K | -27.27%-294K | 63.52%-89K | -65.18%-702K | 111.45%19K | -40.57%-246K | -344.23%-231K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -61.78%-419K | 92.64%-2.28M | -107.93%-1.09M | 99.36%-281K | -80.11%-643K | 52.30%-259K | -122.58%-30.89M | -48.92%13.76M | -285.70%-43.75M | -100.43%-357K |
| Net issuance payments of debt | -124.32%-581K | 94.16%-2.63M | -259.61%-1.29M | 99.01%-432K | -81.23%-647K | 55.03%-259K | -267.85%-45.05M | -101.35%-359K | -69,350.79%-43.75M | -164.32%-357K |
| Net common stock issuance | ---- | --0 | ---- | ---- | ---- | ---- | -86.98%14.12M | ---- | ---- | ---- |
| Proceeds from stock option exercised by employees | --162K | 941.18%354K | 19,800.00%199K | --151K | --4K | --0 | -97.76%34K | -99.72%1K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -61.78%-419K | 92.64%-2.28M | -107.93%-1.09M | 99.36%-281K | -80.11%-643K | 52.30%-259K | -122.58%-30.89M | -48.92%13.76M | -285.70%-43.75M | -100.43%-357K |
| Net cash flow | ||||||||||
| Beginning cash position | 25.48%118.93M | -49.46%94.78M | 20.03%120.55M | -17.80%128.56M | -17.08%138.99M | -49.46%94.78M | 147.27%187.52M | -35.68%100.43M | 12.16%156.4M | 146.93%167.61M |
| Current changes in cash | -175.00%-33.28M | 123.53%23.55M | 65.09%-1.41M | 86.31%-8.13M | 26.88%-11.28M | 308.79%44.38M | -190.67%-100.1M | -113.25%-4.05M | -487.24%-59.36M | -121.05%-15.43M |
| Effect of exchange rate changes | 142.77%71K | -91.85%599K | 86.74%-213K | -96.52%118K | -79.63%860K | -112.37%-166K | 469.40%7.35M | -295.85%-1.61M | 147.85%3.39M | 341.81%4.22M |
| End cash Position | -38.33%85.71M | 25.48%118.93M | 25.48%118.93M | 20.03%120.55M | -17.80%128.56M | -17.08%138.99M | -49.46%94.78M | -49.46%94.78M | -35.68%100.43M | 12.16%156.4M |
| Free cash flow | -135.58%-15.86M | 129.15%20.18M | 66.76%-5.92M | 49.73%-7.85M | 29.41%-10.64M | 315.29%44.59M | -161.23%-69.22M | -600.56%-17.82M | -89.63%-15.61M | -50.28%-15.08M |
| Currency Unit | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg